Skip to main content
Zai Lab Limited logo

Zai Lab Limited — Investor Relations & Filings

Ticker · 9688 ISIN · KYG9887T1168 LEI · 549300P2UYQ9U5LY1T58 HKEX Manufacturing
Open in API
Filings indexed 388 across all filing types
Latest filing 2020-10-09 Capital/Financing Update
Country KY Cayman Islands
Listing HKEX 9688

About Zai Lab Limited

http://www.zailaboratory.com

Zai Lab Limited is an innovative, research-based, commercial-stage biopharmaceutical company dedicated to discovering, developing, and commercializing transformative therapies that address medical conditions with significant unmet needs. The company focuses its pipeline and development efforts across four core therapeutic areas: oncology, immunology, neuroscience, and infectious disease. Zai Lab employs a strategy of internal research and global partnerships to advance best-in-class and first-in-class medicines. A key commercial product is ZEJULA (niraparib), utilized as a maintenance treatment for ovarian cancer in markets including mainland China.

Recent filings

Filing Released Lang Actions
FULL EXERCISE OF THE OVER-ALLOTMENT OPTION
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the full exercise of the over-allotment option related to a global offering of shares by Zai Lab Limited. It includes details about the number of shares issued, the price, approval of listing by the Hong Kong Stock Exchange, and use of proceeds. The document is not a financial report, earnings release, or management discussion, but rather an update on a capital market transaction involving share issuance. It is not a report publication announcement since it contains substantive information about the transaction itself. Therefore, it fits best under the category of Capital/Financing Update (CAP). The document length is 4477 characters, which is sufficient to provide detailed information about the financing event.
2020-10-09 English
CLARIFICATION ANNOUNCEMENT
Capital/Financing Update Classification · 95% confidence The document is titled 'CLARIFICATION ANNOUNCEMENT' and refers to corrections in a previous announcement about offer price and allotment results related to a Global Offering. It clarifies typographical errors in a prior 'Allotment Results Announcement' dated September 25, 2020. The text explicitly states it is an announcement and not a prospectus or financial report. The document length is 4006 characters, which is relatively short and consistent with an announcement rather than a full report. There is no substantive financial data or detailed financial statements present. The content focuses on correcting information in a prior announcement related to share allotment and offer price, which aligns with capital raising activities. Therefore, this document is best classified as a Capital/Financing Update (CAP).
2020-09-25 English
COMPANY INFORMATION SHEET
Regulatory Filings Classification · 95% confidence The document is titled 'Company Information Sheet' and is provided by Zai Lab Limited. It contains detailed information about waivers and exemptions granted by the Hong Kong Stock Exchange and the Securities and Futures Commission (SFC), references to the company's prospectus, and compliance with listing rules. The document discusses accounting standards adoption, disclosure requirements related to the accountants' report, and exemptions granted for certain financial disclosures. It is not a full financial report like an Annual Report (10-K) or Interim Report (IR), nor is it a simple announcement or certification. The document serves as a comprehensive information sheet about the company, its regulatory compliance, and listing-related disclosures, which aligns with the characteristics of a Regulatory Filing (RNS) as a general regulatory announcement and compliance document that does not fit other specific categories. The length (15,000 characters) and content confirm it is not a brief announcement or proxy material. Therefore, the best classification is Regulatory Filings (RNS).
2020-09-25 English
AMENDED AND RESTATED MEMORANDUM AND ARTICLES OF ASSOCIATION
Governance Information Classification · 100% confidence The document is a detailed legal text containing the Memorandum of Association and Articles of Association of Zai Lab Limited, including company structure, share capital, directors' powers, and governance rules. It references the Companies Law of the Cayman Islands and includes detailed provisions about shares, voting rights, and company governance. There is no indication that this is a financial report, earnings release, or announcement. Instead, it is a governance document outlining the internal rules and structure of the company. Therefore, the document fits the category of Governance Information (CGR). The document length (15,000 characters) and content confirm it is a full governance document, not a brief announcement or summary.
2020-09-25 English
ANNOUNCEMENT OF OFFER PRICE AND ALLOTMENT RESULTS
Regulatory Filings Classification · 95% confidence The document is an official announcement from the Hong Kong Stock Exchange (HKEX) regarding the 'IPO Allotment Results' for Zai Lab Limited. It provides links to various files detailing the results of share applications, identification numbers of successful applicants, and instructions for share certificate collection. Since this document serves as the official notification and publication of the IPO allotment results rather than the financial report itself, it falls under the category of regulatory filings or announcements related to share issuance/capital changes. Given the specific nature of IPO allotment results, 'RNS' (Regulatory Filings) is the most appropriate fallback category for this type of exchange-mandated disclosure.
2020-09-25 English
ANNOUNCEMENT OF OFFER PRICE
Capital/Financing Update Classification · 95% confidence The document is an announcement from Zai Lab Limited regarding the final offer price for its Global Offering, including details about the International Offering and Hong Kong Public Offering. It discusses the expected listing date, the gross proceeds, the over-allotment option, and the intended use of proceeds. The document also mentions regulatory compliance and waiver from the Hong Kong Stock Exchange. There are no financial statements or detailed financial performance data presented, nor is this a full report. The document is an announcement related to capital raising and share issuance activities, specifically about the offer price and terms of the public offering. Therefore, it fits best under the category of Capital/Financing Update (CAP). The document length is sufficient and contains substantive information about the offering, not just a brief notice or a report publication announcement.
2020-09-22 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.